VYGR
Voyager Therapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $-0.50 EPS, $6.16M rev
Last earnings -5.0% on 2026-05-07
$3.59
▲ +1.13%$3.59▲ +20.88%
over 1Y
L $2.94EODHDH $5.33
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.1%
1W-4.6%
1M-7.3%
3M-14.0%
YTD-11.9%
1Y+19.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.29x); but revenue fell -49.5% YoY.
Voyager Therapeutics, Inc. shows $40.4M in FY2025 revenue (-49.5% YoY), a -296.5% net margin, and -61.1% ROE.
Sources: SEC EDGAR (CIK 0001640266, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:40:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.